Please assess the completion status of the following clinical trial:

Trial Title: Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* English speaking~* DSM5 diagnosis of opioid use disorder~* Receiving buprenorphine or methadone for treatment of opioid use disorder~* Agreeable to abstaining from using any cannabis or CBD products for the duration of the trial.~Exclusion Criteria:~* Any self-reported use of cannabis or CBD products in the past 30 days~* Baseline depression (PHQ9) or anxiety (GAD7) scores of greater than 10~* Currently pregnant~* Hepatic liver enzymes greater than 3x upper normal limit~* Hypersensitivity to cannabinoids or sesame oil (CBD solution comes in sesame oil emulsion)~* Currently taking any medications with known significant pharmacokinetic interactions with CBD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cannabidiol 600mg (Type: EXPERIMENTAL): All subjects will receive 600mg of oral cannabidiol in a double-blind fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL. Following administration, a battery of tests will be conducted to examine reward- and stress-related neurocognitive processes.
- Placebo (Type: PLACEBO_COMPARATOR): All subjects will receive a matching placebo in a double-blind fashion. Following administration, a battery of tests will be conducted to examine the impact on reward- and stress-related neurocognitive processes.

Based on this trial design, predict the completion outcome and termination type (if applicable).